Youssef Rddad

seattle, washington, united states

Publications:

MMedCentral

ooncologynewscentral.com

ppatientpower.info

Is this you?

Claim your profile to connect with sources, showcase your work, and earn extra income just by writing great stories.

Claim your profile

About

I am a medical journalist covering oncology news for practioners and patients. Before joining HealthCentral, I covered news with a focus on health and science for several newpapers and wire services, including the Minneapolis Star Tribune, The Associated Press, The Advocate, and more. Check out some of my work below.

Featured Articles

Atezolizumab Combo May Be Superior to TACE for Certain Liver Cancers

Atezolizumab plus bevacizumab demonstrated a longer time to failure of treatment strategy (TTFS) than transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC). The results were based on the first interim an... See more

oncologynewscentral.com•Youssef Rddad•Jan 13, 2026

FDA Rejects CAR-T Approval for Second Time

The U.S. Food and Drug Administration (FDA) declined to approve a CAR T-cell therapy for patients with Epstein-Barr virus–positive posttransplant lymphoproliferative disorder (EBV+ PTLD), marking the second time the FDA has rejected the therapy’s approval... See more

oncologynewscentral.com•Youssef Rddad•Jan 12, 2026

Adjuvant Pembrolizumab Fails in Phase 3 Liver Cancer Trial

Adjuvant pembrolizumab (Keytruda) failed to improve recurrence-free survival (RFS) in patients with hepatocellular carcinoma (HCC) after curative-intent resection or local ablation, leaving no established immunotherapy option in this setting and underscor... See more

oncologynewscentral.com•Youssef Rddad•Jan 12, 2026

Two Phase 3 Trials at ASCO GI Support New Frontline Colorectal Cancer Options

Two phase 3 studies reported distinct first-line advances for molecularly defined subsets of patients with metastatic colorectal cancer (mCRC), including higher response rates with targeted therapy in BRAF V600E–mutated disease and longer disease control ... See more

oncologynewscentral.com•Youssef Rddad•Jan 9, 2026

Ending "Bogus" Quality-of-Life Data in Cancer Trials

In cancer trials, measures of quality of life (QOL) are often buried in complicated averages that tell clinicians little about how patients actually feel while receiving treatment. A recent paper published in the Lancet Oncology00288-8/fulltext) pushes fo... See more

oncologynewscentral.com•Youssef Rddad•Dec 18, 2025

Bylined Articles

HARO Queries

Portfolio

Is this you?

Claim your profile to connect with sources, showcase your work, and earn extra income just by writing great stories.

Claim your profile

Social Media

Pitching Guidelines

Keep it short (under 200 words)
Include credentials and links
Use subject lines with query title

Pitching Guidelines

Quick Stats

Followers

351

Articles45

Last Article9 hours ago

Stats

Education

Bachelors, Journalism, Political Science at University Of MinnesotaGraduated: 2015

Education

Youssef Rddad

Is this you?

About

Featured Articles

Atezolizumab Combo May Be Superior to TACE for Certain Liver Cancers

FDA Rejects CAR-T Approval for Second Time

Adjuvant Pembrolizumab Fails in Phase 3 Liver Cancer Trial

Two Phase 3 Trials at ASCO GI Support New Frontline Colorectal Cancer Options

Ending "Bogus" Quality-of-Life Data in Cancer Trials

Is this you?

Social Media

Education

Connect with journalists.

Connect with journalists.

Featured Articles

Atezolizumab Combo May Be Superior to TACE for Certain Liver Cancers

FDA Rejects CAR-T Approval for Second Time

Adjuvant Pembrolizumab Fails in Phase 3 Liver Cancer Trial

Two Phase 3 Trials at ASCO GI Support New Frontline Colorectal Cancer Options

Ending "Bogus" Quality-of-Life Data in Cancer Trials

Social Media

Education